NTX1-001

NTX1-001 is a potent and selective small molecule inhibitor of the KRAS G12D mutation, developed by Nantox. KRAS G12D is a prevalent oncogenic driver in several aggressive malignancies, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non-small cell lung cancer (NSCLC). Unlike KRAS G12C inhibitors that rely on covalent binding to a cysteine residue, NTX1-001 is designed to non-covalently bind the aspartic acid mutant form of KRAS with high affinity, effectively locking the protein in its inactive GDP-bound state. This inhibition prevents the activation of downstream signaling cascades, such as the MAPK/ERK pathway, thereby suppressing tumor cell proliferation and survival. NTX1-001 has demonstrated robust anti-tumor activity in preclinical models and is currently undergoing Phase 1 clinical evaluation in patients with advanced solid tumors harboring the KRAS G12D mutation.

Other names

NTX1-001NTX-1-001NTX 1-001